RAC 0.93% $1.62 race oncology ltd

Ann: Notification regarding unquoted securities - RAC, page-53

  1. 52 Posts.
    lightbulb Created with Sketch. 111
    That a very interesting point you raise. A colleague of mine is dealing with serious Melanoma and currently receiving Keytruda treatment. I had mentioned Bisantrene and suggested that he talk with his oncologist about possible compassionate use.

    I was talking to him today about this and after I got of the phone I did start thinking about the in human efficacy data Race/Dr T are very likely to have as a result of compassionate use of Bisantrene but cannot make public.

 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.